Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 5:18:100187.
doi: 10.1016/j.pacs.2020.100187. eCollection 2020 Jun.

Photoacoustic imaging for three-dimensional visualization and delineation of basal cell carcinoma in patients

Ulf Dahlstrand  1 , Rafi Sheikh  1 , Aboma Merdasa  1 , Rehan Chakari  1 , Bertil Persson  2 , Magnus Cinthio  3 , Tobias Erlöv  3 , Bodil Gesslein  1 , Malin Malmsjö  1
Affiliations

Photoacoustic imaging for three-dimensional visualization and delineation of basal cell carcinoma in patients

Ulf Dahlstrand et al. Photoacoustics. .

Abstract

Background: Photoacoustic (PA) imaging is an emerging non-invasive biomedical imaging modality that could potentially be used to determine the borders of basal cell carcinomas (BCC) preoperatively in order to reduce the need for repeated surgery.

Methods: Two- and three-dimensional PA images were obtained by scanning BCCs using 59 wavelengths in the range 680-970 nm. Spectral unmixing was performed to visualize the tumor tissue distribution. Spectral signatures from 38 BCCs and healthy tissue were compared ex vivo.

Results and discussion: The PA spectra could be used to differentiate between BCC and healthy tissue ex vivo (p < 0.05). Spectral unmixing provided visualization of the overall architecture of the lesion and its border.

Conclusion: PA imaging can be used to differentiate between BCC and healthy tissue and can potentially be used to delineate tumors prior to surgical excision.

Keywords: Basal cell carcinoma; Basalioma; Human; Patients; Photoacoustic imaging; Spectral unmixing; Tissue differentiation.

PubMed Disclaimer

Conflict of interest statement

A conflicting interest exists when professional judgement concerning a primary interest (such as patient’s welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Figures

Fig. 1
Fig. 1
Photographs of the ex vivo examination setup. (A) An excised lesion suspended in a saline solution. (B) The PA probe attached to an adjustable arm with the stepping motor, used for the examinations.
Fig. 2
Fig. 2
The mean PA spectra obtained from BCCs and the surrounding healthy tissue from ex vivo measurements. The dispersion (± one standard deviation) is indicated by the shaded areas. A clear difference can be seen in the spectral signatures of the BCCs and healthy tissue (p < 0.05 for 760 to 945 nm, n=38).
Fig. 3
Fig. 3
Representative example of an ex vivo scan of a nodular BCC. The image on the upper left shows the small ROIs superimposed on the ultrasound image. The scale bar is 1 mm. The PA spectra obtained from the ROIs are given below, showing the change from cancerous to healthy tissue. The image on the upper right shows the same H&E-stained histological sample.
Fig. 4
Fig. 4
Representative example of a spectrally unmixed 3D multiwavelength PA image of a nodular BCC lesion examined ex vivo. The suspected cancerous tissue is shown as a purple overlay. The colorbar represents the unmixed signal for BCC tissue (a.u.). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 5
Fig. 5
Representative example of a spectrally unmixed 3D multiwavelength PA image of a superficial BCC lesion examined ex vivo. The suspected cancerous tissue is shown as a purple overlay. The colorbar represents the unmixed signal for BCC tissue (a.u.). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
See this image and copyright information in PMC

References

    1. Lomas A., Leonardi-Bee J., Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br. J. Dermatol. 2012;166(5):1069–1080. - PubMed
    1. Cameron M.C., Lee E., Hibler B., Barker C.A., Mori S., Cordova M., Nehal K.S., Rossi A.M. Basal cell carcinoma: part 1. J. Am. Acad. Dermatol. 2018 - PubMed
    1. Lewis K.G., Weinstock M.A. Nonmelanoma skin cancer mortality (1988–2000): the Rhode island follow-back study. Arch. Dermatol. 2004;140(7):837–842. - PubMed
    1. Mohan S.V., Chang A.L. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. Curr. Dermatol. Rep. 2014;3:40–45. - PMC - PubMed
    1. Thomas D.J., King A.R., Peat B.G. Excision margins for nonmelanotic skin cancer. Plast. Reconstr. Surg. 2003;112(1):57–63. - PubMed

LinkOut - more resources